Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of One Dose Cecolin vs Gardasil
NCT06345885Phase 4Completed
- Sponsor
- Xiamen Innovax Biotech Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus bivalent (types 16, 18) vaccine in human papillomavirus infection, sponsored by Xiamen Innovax Biotech Co., Ltd.. Started Feb 2023; status: completed.
02
Drugs
recombinant human papillomavirus bivalent (types 16, 18) vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06345885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345885.